• Global UAV entered a definitive agreement to combine with private biotech Nexus Peptide Sciences via a three-cornered amalgamation.
• Nexus shareholders to receive 20,500,000 Global UAV shares, plus 7,000,000 transferable warrants exercisable at CAD 0.1 for two years.
• Deal terms assume no more than 33,000,000 shares, plus 17,000,000 warrants, outstanding immediately before closing.
• Concurrent equity financing targeted at CAD 3-5 million, selling 7,500,000-12,500,000 shares at CAD 0.4 each.
• Closing targeted by Sept. 30, 2026; post-deal board set at five directors, including three Nexus nominees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global UAV Technologies Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608240917NEWSFILECNPR____20260824_311038_1) on August 24, 2026, and is solely responsible for the information contained therein.